

CLAVASEPTIN P 50 MG TABLETS FOR DOGS AND CATS

Authorised

- Amoxicillin trihydrate
- Potassium clavulanate

Product identification

Medicine name:

CLAVASEPTIN P 50 MG TABLETS FOR DOGS AND CATS

CLAVASEPTIN 50 mg COMPRIMIDOS SABOR PARA PERROS Y GATOS

Active substance:

Amoxicillin trihydrate

Potassium clavulanate

Target species:

Dog

Cat

Route of administration:

Oral use

Product details

Active substance and strength:

Amoxicillin trihydrate

45.91 milligram(s) / 1.00 Tablet

Potassium clavulanate
11.91 milligram(s) / 1.00 Tablet

Pharmaceutical form:

Tablet

Withdrawal period by route of administration:

Oral use:

-

Dog

-

Cat

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QJ01CR02

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Spain

Package description:

Cardboard box of 1 blister of 10 tablets

Cardboard box of 100 blisters of 10 tablets

Cardboard box of 75 blisters of 10 tablets

Cardboard box of 60 blisters of 10 tablets

Cardboard box of 50 blisters of 10 tablets

Cardboard box of 40 blisters of 10 tablets

Cardboard box of 30 blisters of 10 tablets

Cardboard box of 25 blisters of 10 tablets

Cardboard box of 20 blisters of 10 tablets

Cardboard box of 15 blisters of 10 tablets

Cardboard box of 12 blisters of 10 tablets

Cardboard box of 10 blisters of 10 tablets

Cardboard box of 5 blisters of 10 tablets

Cardboard box of 2 blisters of 10 tablets

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Legal basis not covered by Directive 2001/82/EC

Marketing authorisation holder:

Vetoquinol Especialidades Veterinarias S.A.

Marketing authorisation date:

5/12/2005

Manufacturing sites for batch release:

Vetoquinol S.A.

Responsible authority:

Spanish Agency Of Medicines And Medical Devices

Authorisation number:

1662 ESP

Date of authorisation status change:

5/12/2005

Reference member state:

France

Procedure number:

FR/V/0407/001

Concerned member states:

Austria Belgium Bulgaria Cyprus Czechia Denmark Finland Germany
Greece Hungary Ireland Italy Latvia Lithuania Luxembourg Netherlands
Poland Portugal Romania Slovakia Slovenia Spain Sweden
United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Labelling

This document does not exist in this language (English). You can find it in another language below.